(4) Inventory

After approval of Vascepa on July 26, 2012 by the FDA, the Company began capitalizing its purchases of saleable inventory of Vascepa from suppliers that have been qualified by the FDA. Inventories consist of the following (in thousands):


	December 31, 2013		December 31, 2012
Raw materials, current	$	4,246	$	5,465
Work in process		11,310		15,471
Finished goods		5,026		326
Finished goods inventory held by others		627		—

Total inventory, current		21,209		21,262

Raw materials, long-term		5,482		—

Total inventory	$	26,691	$	21,262

During the year ended December 31, 2013, the Company wrote off $1.8 million of inventories deemed to be unrecoverable. The charge was recorded within research and development expense in the statement of operations as this supplier has yet to produce material qualified for commercial sale. In addition, $5.5 million of raw material inventory was reclassified to long-term inventory, as it is not anticipated to be sold within the next twelve months based on current estimates.